Pfizer Gestione
Criteri Gestione verificati 3/4
Pfizer Il CEO è Albert Bourla, nominato in Jan2019, e ha un mandato di 7.58 anni. la retribuzione annua totale è $ 27.59M, composta da 6.5% di stipendio e 93.5% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.007% delle azioni della società, per un valore di $ 10.55M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 6.3 anni e 7.8 anni.
Informazioni chiave
Albert Bourla
Amministratore delegato
US$27.6m
Compenso totale
| Percentuale dello stipendio del CEO | 6.53% |
| Mandato del CEO | 7.6yrs |
| Proprietà del CEO | 0.007% |
| Durata media del management | 6.3yrs |
| Durata media del Consiglio di amministrazione | 7.8yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Aggiornamento narrativa • Aug 05
PFE: Pipeline Readouts And Legal Overhang Will Shape Post Covid Earnings Trajectory
The analyst fair value estimate for Pfizer has risen from $24.00 to $25.00 as analysts factor in updated pipeline expectations, modestly stronger profit margin assumptions, and recent Street price target moves that cluster in the mid to high $20s per share. Analyst Commentary Recent Street views on Pfizer sit in a fairly tight range in the mid to high US$20s, with most price targets clustered between US$25 and US$35.Seeking Alpha • Jul 27
Pfizer: Calling The Bottom - The Patent Cliff Is Real, But The Valuation Has Fallen Too Far
Summary I initiate Pfizer with a contrarian BUY rating and a $32 price target for 2026 Q3-Q4. PFE’s non-COVID portfolio demonstrates resilience, with Padcev, Vyndamax, and new launches driving operational growth despite patent cliffs. Padcev’s July 2026 approval expands its addressable market, while pipeline assets like Berobenatide and PF-08634404 offer additional upside. Valuation reflects patent-cliff risk, but strong cash flow, dividend support, and underappreciated pipeline provide a favorable risk/reward setup. Read the full article on Seeking Alpha
Aggiornamento narrativa • Jul 13
PFE: Oncology And Obesity Pipeline Will Drive Post Patent Cliff Repricing
Pfizer's analyst price target has edged lower by about $0.80, reflecting updated models that factor in softer revenue expectations, slightly higher long term margin assumptions, and a reset of near term enthusiasm following multiple target cuts and a downgrade to Hold from several firms ahead of upcoming earnings catalysts. Analyst Commentary Recent research on Pfizer points to a mix of caution and optimism, with several firms trimming price targets while still seeing room for the stock to re-rate as execution on the core portfolio, business development and upcoming data readouts play through.Aggiornamento narrativa • Jun 22
PFE: Oncology And Obesity Pipeline Progress Will Balance Patent Cliff Risks
Pfizer's analyst price target edges up by $1 to $26, as analysts point to a more balanced risk and reward profile supported by recent guidance commentary, oncology pipeline milestones, and updated views on longer term revenue and margin assumptions. Analyst Commentary Recent research coverage around Pfizer highlights a mix of upgraded ratings, modest price target increases and ongoing questions around specific product exposures and partnership choices.Articolo di analisi • Jun 20
Pfizer (PFE) Stock Could Be 10% Undervalued After CFO Exit Raises Execution Questions
Pfizer (PFE) is back in focus after the company said Chief Financial Officer Dave Denton will leave in August, with long-time finance executive Cecile Guegan stepping in as interim CFO during the search for a successor. See our latest analysis for Pfizer. The CFO announcement comes as Pfizer shares trade at US$25.21, with the stock down over the past quarter but posting a 12.52% total shareholder return over the last year. This suggests that shorter term momentum has cooled even as income and...Aggiornamento narrativa • Jun 08
PFE: Oncology And Obesity Pipeline Will Support Post Patent Cliff Repricing
Narrative update Pfizer's analyst price targets have inched higher, with a recent move such as Wolfe Research lifting its view to $26 from $25 as analysts factor in elements like the five-year sales outlook and extended Vyndamax exclusivity, while also accounting for COVID-related uncertainty in their updated assumptions. Analyst Commentary Recent Street commentary on Pfizer centers on two themes investors should keep in mind: how analysts are framing post COVID revenue visibility and how legal and partnership developments may affect long term cash flow and valuation support.
Aggiornamento narrativa • May 25
PFE: Obesity And Oncology Pipeline Progress Will Drive Long-Term Upside Potential
Analysts have nudged Pfizer's implied fair value slightly higher to about $29.19 per share, reflecting a series of mostly modest price target increases, including Wolfe Research's move to $26. This comes alongside updated views on long term sales, COVID uncertainty, patent settlements around Vyndamax, and the recent Veppanu licensing, as well as GLP-1 and oncology pipeline commentary.Aggiornamento narrativa • May 03
PFE: Patent Cliff And GLP 1 Pipeline Will Shape Post Settlement Outlook
Pfizer's updated analyst price target has shifted slightly lower to $24.00 from $25.00 as analysts factor in a steeper projected revenue decline, a modestly higher profit margin outlook, and mixed views on the post-settlement pipeline and patent overhang. Analyst Commentary Recent research on Pfizer highlights a split view.Aggiornamento narrativa • Apr 19
PFE: GLP-1 And Oncology Advancements Will Support Post LOE Repricing
Pfizer's analyst fair value estimate has been adjusted modestly higher to $35.96 from $35.33, as analysts factor in recent price target raises and mixed views on the post-2028 pipeline, loss of exclusivity risks, and evolving expectations for the GLP-1 and oncology portfolios. Analyst Commentary Recent Street research on Pfizer reflects a split view, with some firms expressing caution around patent expiries and near term visibility, while other bullish analysts focus on the potential in GLP-1 and oncology programs, along with broader sector appeal in healthcare.Aggiornamento narrativa • Apr 05
PFE: Obesity And Oncology Pipeline Progress Will Drive Post LOE Rerating
Analysts have nudged Pfizer's implied fair value modestly higher to about $35.33 per share, citing recent price target increases of around $1 to $3 and research that highlights contributions from its GLP-1, oncology, and hematology pipelines, while also noting the long-term patent cliff and revenue uncertainty. Analyst Commentary Recent research on Pfizer shows a split view, with some firms highlighting long term headwinds from loss of exclusivity while others point to pipeline depth and business development as potential offsets.Aggiornamento narrativa • Mar 22
PFE: Patent Cliff And GLP 1 Pipeline Will Shape Post 2028 Outlook
Pfizer's updated analyst narrative keeps fair value steady at $25.00, with recent Street research showing price targets clustering from $25.00 to $35.00 as analysts weigh concerns about a post-2028 patent cliff against interest in the GLP-1, oncology, and collaboration pipelines, as well as healthcare's perceived appeal in a riskier macro backdrop. Analyst Commentary Recent Street research around Pfizer reflects a split view, with some firms pointing to potential in GLP-1, oncology, hematology, and collaborations, while others emphasize the scale and timing of the expected revenue cliff and limited visibility on offsets.Aggiornamento narrativa • Mar 08
PFE: Patent Cliff And GLP 1 Pipeline Will Shape Next Decade
Analysts lifted their fair value estimate for Pfizer from $23.00 to $25.00 per share, reflecting updated views that weigh a stronger GLP 1 and oncology pipeline against ongoing concerns about the patent cliff and near term revenue visibility. Analyst Commentary Recent Street research on Pfizer presents a mixed picture, with more cautious voices focusing on patent expirations, limited near term pipeline visibility, and questions around how quickly new therapies can support growth.Aggiornamento narrativa • Feb 21
PFE: Obesity Pipeline Progress Will Drive Post LOE Re Rating
Pfizer's updated analyst price target edges lower to about $35 per share. This reflects analysts' focus on ongoing losses of exclusivity, a slightly softer revenue and margin outlook, and tempered expectations for future P/E as some firms initiate or assume coverage with more cautious views around the next few years.Aggiornamento narrativa • Feb 07
PFE: Obesity Pipeline And LOE Headwinds Will Shape Future Re Rating
Narrative Update Analysts have trimmed their fair value estimate for Pfizer from $36.16 to $35.46, reflecting more cautious assumptions on revenue trends and profit margins, even as some on the Street highlight new assets and deals that they believe could support a higher future P/E multiple. Analyst Commentary Recent Street research on Pfizer highlights a mix of caution and optimism, with several firms reassessing how the pipeline and recent deals might offset upcoming patent expiries and support the valuation over time.Aggiornamento narrativa • Jan 24
PFE: Loss Of Exclusivity And Obesity Deal Costs Will Pressure Shares
Analysts have reduced their fair value estimate for Pfizer from $24.00 to $23.00 per share, citing lower revenue and margin assumptions, a slightly higher discount rate, and cautious views on patent expiries, while still noting ongoing interest in its pipeline and licensing deals. Analyst Commentary Recent Street research around Pfizer has been mixed, with some firms highlighting long term opportunities in areas like obesity and licensing, while others are stressing near term execution and patent expiry risks.Aggiornamento narrativa • Jan 10
PFE: Obesity Deal And LOE Overhang Will Shape Re Rating Potential
Analysts have trimmed their price expectations for Pfizer, citing ongoing revenue uncertainty around an expected US$15b to US$20b loss of exclusivity over the next few years, even as some see support from the obesity deal and a broader positive stance on large cap biopharma. Analyst Commentary Recent research highlights a split view on Pfizer, with some caution around the expected US$15b to US$20b loss of exclusivity over the next few years and others pointing to potential upside linked to obesity treatments and a broader positive stance on large cap biopharma.Articolo di analisi • Jan 08
Pfizer (NYSE:PFE) Has Announced A Dividend Of $0.43
Pfizer Inc. ( NYSE:PFE ) will pay a dividend of $0.43 on the 6th of March. This makes the dividend yield 6.8%, which...Aggiornamento narrativa • Dec 25
PFE: Obesity Bid And Margin Outlook May Drive Re-Rating Ahead
Analysts have nudged their price target on Pfizer higher by $2 to $30, citing improving margin expectations and a more constructive sector backdrop, despite tempered revenue growth assumptions. Analyst Commentary Bullish analysts highlight that the latest price target increase reinforces a gradually improving sentiment toward Pfizer, with investors starting to look past the near term revenue slowdown and focus more on medium term cash flow durability and pipeline execution.Articolo di analisi • Dec 18
Pfizer (NYSE:PFE) Has Affirmed Its Dividend Of $0.43
The board of Pfizer Inc. ( NYSE:PFE ) has announced that it will pay a dividend of $0.43 per share on the 6th of March...Aggiornamento narrativa • Dec 11
PFE: Obesity Pipeline Expansion Will Drive Upside Amid Sector Rerating
Analysts nudged their price target on Pfizer higher to $30 from $28, citing a sector wide rerating on benign U.S. drug pricing developments and the strategic upside from an expanded obesity pipeline and broader large cap biopharma innovation. Analyst Commentary Bullish analysts highlight that Pfizer is benefiting from a constructive shift in U.S. drug pricing expectations and a broader rerating of large cap biopharma, which supports the recent price target increase and stabilizes valuation multiples.Aggiornamento narrativa • Nov 13
PFE: Obesity Deal Will Drive Upside After Sector Underperformance And Portfolio Shifts
Pfizer’s analyst price target was raised from $28 to $30 per share, reflecting a modest increase in fair value. Analysts cite sector-wide re-rating and updated fundamentals, including acquisition activity and anticipated drug pipeline developments, as key drivers for the revision.Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Jun 28 2026 | n/a | n/a | US$4b |
| Mar 29 2026 | n/a | n/a | US$7b |
| Dec 31 2025 | US$28m | US$2m | US$8b |
| Sep 28 2025 | n/a | n/a | US$10b |
| Jun 29 2025 | n/a | n/a | US$11b |
| Mar 30 2025 | n/a | n/a | US$8b |
| Dec 31 2024 | US$25m | US$2m | US$8b |
| Sep 29 2024 | n/a | n/a | US$4b |
| Jun 30 2024 | n/a | n/a | -US$3b |
| Mar 31 2024 | n/a | n/a | -US$288m |
| Dec 31 2023 | US$22m | US$2m | US$2b |
| Oct 01 2023 | n/a | n/a | US$10b |
| Jul 02 2023 | n/a | n/a | US$21b |
| Apr 02 2023 | n/a | n/a | US$29b |
| Dec 31 2022 | US$33m | US$2m | US$31b |
| Oct 02 2022 | n/a | n/a | US$30b |
| Jul 03 2022 | n/a | n/a | US$29b |
| Apr 03 2022 | n/a | n/a | US$25b |
| Dec 31 2021 | US$24m | US$2m | US$22b |
| Oct 03 2021 | n/a | n/a | US$19b |
| Jul 04 2021 | n/a | n/a | US$12b |
| Apr 04 2021 | n/a | n/a | US$9b |
| Dec 31 2020 | US$21m | US$2m | US$7b |
| Sep 27 2020 | n/a | n/a | US$212m |
| Jun 28 2020 | n/a | n/a | US$7b |
| Mar 29 2020 | n/a | n/a | US$9b |
| Dec 31 2019 | US$18m | US$2m | US$11b |
Compensazione vs Mercato: La retribuzione totale di Albert ($USD 27.59M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 14.43M ).
Compensazione vs guadagni: La retribuzione di Albert è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Albert Bourla (64 yo)
7.6yrs
Mandato
US$27,585,301
Compensazione
Dr. Albert Bourla, DVM, Ph.D. serves as Chairman & CEO at Pfizer Venture Investments LLC. He serves as CEO from January 2019. He serves as the Chief Executive Officer of Pfizer Inc. since January 1, 2019 a...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Chairman of the Board & CEO | 7.6yrs | US$27.59m | 0.0069% $ 10.6m | |
| Executive VP & CFO | 4.3yrs | US$9.67m | 0.00067% $ 1.0m | |
| Chief Scientific Officer and President of Research & Development | 1.6yrs | US$10.01m | 0.0028% $ 4.3m | |
| Executive VP & Chief Legal Officer | 12.7yrs | US$9.11m | 0.0029% $ 4.4m | |
| Executive VP & Chief U.S. Commercial Officer | 5yrs | US$9.43m | 0.00052% $ 793.1k | |
| Senior VP | 6.4yrs | Nessun dato | 0.00050% $ 762.6k | |
| Executive VP & Chief Information Officer | less than a year | Nessun dato | 0.00083% $ 1.3m | |
| Chief Investor Relations Officer | no data | Nessun dato | Nessun dato | |
| Chief People Experience Officer & Executive VP | 6.2yrs | Nessun dato | 0.00074% $ 1.1m | |
| Senior VP and Chief Scientific Officer of Inflammation & Immunology | 10.3yrs | Nessun dato | Nessun dato | |
| Chief Scientific Officer of Oncology | 7.1yrs | Nessun dato | Nessun dato | |
| Senior VP & Chief Scientific Officer of Rare Disease | no data | Nessun dato | Nessun dato |
6.3yrs
Durata media
60yo
Età media
Gestione esperta: Il team dirigenziale di PFE è esperto e expertise (durata media dell'incarico 6.3 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Chairman of the Board & CEO | 6.6yrs | US$27.59m | 0.0069% $ 10.6m | |
| Independent Director | 6.3yrs | US$380.52k | 0.000060% $ 91.5k | |
| Lead Independent Director | 12.9yrs | US$410.00k | Nessun dato | |
| Independent Director | 9.5yrs | US$360.00k | 0.0013% $ 1.9m | |
| Independent Director | 18.9yrs | US$410.00k | 0.00018% $ 274.5k | |
| Independent Director | 12.2yrs | US$390.00k | 0.000060% $ 91.5k | |
| Independent Director | 1.8yrs | US$360.00k | 0.00066% $ 1.0m | |
| Independent Director | 8.4yrs | US$380.00k | Nessun dato | |
| Independent Director | 6.5yrs | US$380.00k | Nessun dato | |
| Independent Director | 2.2yrs | US$380.00k | 0.00018% $ 274.5k | |
| Independent Director | 7.2yrs | US$393.50k | 0.00018% $ 274.5k | |
| Independent Director | 11.2yrs | US$400.37k | Nessun dato |
7.8yrs
Durata media
65yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di PFE sono considerati esperti (durata media dell'incarico 7.8 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/08/09 07:22 |
| Prezzo dell'azione a fine giornata | 2026/08/07 00:00 |
| Utili | 2026/06/28 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Pfizer Inc. è coperta da 44 analisti. 25 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| David Toung | Argus Research Company |
| Emily Field | Barclays |
| Kerry Holford | Berenberg |